Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
...

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, an...

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Anitocabtagene Autoleucel
Drug: Pomalidomide
Drug: Cyclophosphamide
Drug: Bortezomib
Drug: Fludarabine
Drug: Dexamethasone
Drug: Daratumumab
Drug: Carfilzomib

First Posted Date: 2024-05-14

Last Posted Date: 2024-12-19

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 450

Registration Number: NCT06413498

Locations: 🇺🇸
UCLA Department of Medicine-Hematology/Oncology, Santa Monica, California, United States
🇺🇸
Baptist Cancer Center, Memphis, Tennessee, United States
🇦🇺
Epworth HealthCare, Richmond, Victoria, Australia

and more 4 locations

Efficacy and Safety of Local Glucocorticoids for the Treatment of Acute Radiation-Induced Intestinal Injury

Not Applicable

Recruiting

Conditions: Radiation-Induced Intestinal Injury

Interventions: Drug: Dexamethasone
Drug: Antibiotics, probiotics, vitamins, antidiarrheal drugs, enteral nutrition, and endoscopic argon plasma coagulation

First Posted Date: 2024-05-13

Last Posted Date: 2024-08-07

Lead Sponsor: General Hospital of Shenyang Military Region

Target Recruit Count: 60

Registration Number: NCT06410443

Locations: 🇨🇳
Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area), Shenyang, Liaoning, China

Comparison Between Ketamine Intrathecal and iv Dexamethasone for Post Cesarean Analgesia

Phase 4

Not yet recruiting

Conditions: Post Cesarean Analgesia

Interventions: Drug: Ketamine
Drug: dexamethasone

First Posted Date: 2024-05-10

Last Posted Date: 2024-05-10

Lead Sponsor: Assiut University

Target Recruit Count: 90

Registration Number: NCT06408974

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Not yet recruiting

Conditions: Newly Diagnosed
High Risk
MRD
Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Daratumumab
Drug: Lenalidomide
Drug: Dexamethasone
Drug: VRD for first-cycle induction therapy

First Posted Date: 2024-05-10

Last Posted Date: 2024-05-10

Lead Sponsor: The First Affiliated Hospital of Soochow University

Target Recruit Count: 45

Registration Number: NCT06409702

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Phase 2

Not yet recruiting

Conditions: T-cell Lymphoma
T-cell Acute Lymphoblastic Leukemia
Mixed Phenotype Acute Leukemia

Interventions: Drug: Dexamethasone
Drug: Vincristine
Drug: Daunorubicin
Drug: Calaspargase pegol
Drug: Venetoclax
Drug: Bortezomib
Drug: Dasatinib
Drug: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Mercaptopurine
Drug: Nelarabine
Drug: Methotrexate
Drug: Thioguanine

First Posted Date: 2024-04-30

Last Posted Date: 2024-12-16

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 145

Registration Number: NCT06390319

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Efficacy and Safety of Sivelestat Sodium and Dexamethasone in the Treatment of ARDS

Not Applicable

Recruiting

Conditions: Acute Respiratory Distress Syndrome

Interventions: Drug: Sivelestat sodium
Drug: Dexamethasone
Drug: Dexamethasone placebo
Drug: Sivelestat sodium placebo

First Posted Date: 2024-04-29

Last Posted Date: 2024-06-04

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 300

Registration Number: NCT06387823

Locations: 🇨🇳
Luoyang Central Hospital, Luoyang, Henan, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
Yanan University Affiliated Hospital, Yanan, Shaanxi, China

and more 1 locations